Organovo Holdings (Organovo Holdings) GF Value : $18.06 (As of Apr. 30, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Organovo Holdings GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-30), Organovo Holdings's share price is $1.08. Organovo Holdings's GF Value is $18.06. Therefore, Organovo Holdings's Price-to-GF-Value for today is 0.06.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Organovo Holdings is Possible Value Trap, Think Twice.

Organovo Holdings (NAS:ONVO) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Organovo Holdings's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.08	/	18.06
	=	0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organovo Holdings GF Value Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Organovo Holdings (Organovo Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (NAS:ONVO) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

4OR1:Germany

Address

11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121

Website

https://www.organovo.com

Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.

Executives

David Gobel	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi	director	C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern	director	STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess	officer: President, CFO and PFO	366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen	officer: General Counsel & Secretary	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner	officer: Chief Scientific Officer	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig	officer: President and CFO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy	director, officer: Executive Chairman	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes	officer: Chief Medical Officer	6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins	officer: EVP, Research & Development	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch	director, officer: CEO & President	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075